Tag:

AstraZeneca

Latest Headlines

Latest Headlines

Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues

Will Pfizer come back at AstraZeneca? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals.

AstraZeneca deepens its Cambridge ties with hopes for Alzheimer's and cancer

AstraZeneca, two years away from a big relocation to Cambridge, U.K., is broadening its relationship with the local university, signing a slew of new agreements that will bolster its R&D efforts in neuroscience and oncology.

AstraZeneca's $2B cancer contender lines up for EU scrutiny

AstraZeneca is expecting word from European regulators next week on whether they'll recommend approval for its new ovarian cancer treatment, a drug the company hopes can bring in $2 billion a year at its peak.

AstraZeneca photo campaign helps cancer patients swap stories on social media

AstraZeneca has launched a photo-sharing campaign on Twitter, Instagram and other social media sites to get women talking about their metastatic breast cancer (MBC).

Pictures tell the story in AstraZeneca's breast cancer photo-sharing push

Pharma companies are no stranger to photography-based disease awareness campaigns. But there's something different about AstraZeneca's latest breast cancer photo campaign: The photographers are the patients themselves.

UPDATED: Texas AG: AstraZeneca paid $465K in kickbacks, committed fraud in Seroquel marketing

Texas Attorney General Greg Abbott has sued AstraZeneca for fraud, saying that AstraZeneca sales reps misled doctors and state Medicaid officials about Seroquel's side effects, paid kickbacks to two influential state decision-makers, and promoted the powerful antipsychotic for off-label uses.

With help from Charles River, AstraZeneca expands its respiratory pipeline

AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.

AstraZeneca finally bails on troubled Targacept after years of failure

After 9 years of fruitless work on treatments for Alzheimer's disease and depression, AstraZeneca is dissolving its partnership with Targacept, leaving the battered biotech to pick up the pieces of its dwindling pipeline.

AstraZeneca touts upbeat asthma data for key respiratory candidate

It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.

AstraZeneca gets some upbeat asthma data to back would-be IL-5 blockbuster

After acknowledging a midstage setback for its key respiratory drug benralizumab in COPD last month, AstraZeneca's big MedImmune division has come back with positive, though somewhat mixed, Phase IIb data underscoring the effectiveness of knocking down eosinophils--white blood cells--in preventing asthma attacks.